Larotrectinib (Vitrakvi®). HTA ID: 19050

Assessment Status NCPE Assessment Process Complete
HTA ID 19050
Drug Larotrectinib
Brand Vitrakvi®
Indication For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
Assessment Process
Rapid review completed 13/01/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 20/01/2020
Pre-submission consultation with Applicant 20/04/2020
Full submission received from Applicant 11/02/2021
Preliminary review sent to Applicant 16/07/2021
NCPE assessment re-commenced 30/08/2021
Follow-up to preliminary review sent to Applicant 10/09/2021
NCPE assessment re-commenced 15/09/2021
Additional follow-up to Preliminary Review sent to Applicant 05/10/2021
NCPE assessment re-commenced 13/10/2021
Factual accuracy sent to Applicant 22/10/2021
NCPE assessment re-commenced 03/11/2021
NCPE assessment completed 23/11/2021
NCPE assessment outcome The NCPE recommends that larotrectinib (Vitrakvi®) not be recommended for reimbursement, unless cost effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations; May 2023